FDA adcomm votes narrowly against Veru’s Covid drug, citing uncertainties amid mortality benefit in small trial

The FDA’s Pulmonary-Allergy Drugs Advisory Committee on Wednesday voted 8-5 against Veru’s repurposed cancer drug, sabizabulin, as a treatment for certain hospitalized adults with Covid-19, arguing the benefits do not outweigh the risks.

The vote against Veru’s drug followed a close dissection of the pivotal randomized, double-blind, placebo-controlled clinical trial...

Click to view original post